**Core Concept**
Cis-atracurium is a stereoisomer of atracurium, a non-depolarizing neuromuscular blocking agent. The preference for cis-atracurium over atracurium is based on its pharmacokinetic profile and reduced side effects.

**Why the Correct Answer is Right**
Cis-atracurium has a more favorable profile due to its reduced metabolism via the Hoffmann elimination pathway, which is prone to producing toxic metabolites. Additionally, cis-atracurium undergoes ester hydrolysis, a more predictable and safer process. This results in fewer side effects such as histamine release and a more consistent onset and duration of action.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is not relevant to the comparison between cis-atracurium and atracurium.
**Option B:** Metabolism via the Hoffmann elimination pathway is actually a disadvantage of atracurium, not a benefit.
**Option C:** Atracurium's metabolism via the Hoffmann elimination pathway is not a characteristic of cis-atracurium.

**Clinical Pearl / High-Yield Fact**
Cis-atracurium is preferred over atracurium due to its reduced propensity for histamine release and more predictable metabolism, making it a safer choice for neuromuscular blockade.

**Correct Answer:**
Correct Answer: C.